Literature DB >> 105363

Sensitivity of fatty acid cyclooxygenase from human aorta to acetylation by aspirin.

J W Burch, N L Baenziger, N Stanford, P W Majerus.   

Abstract

The rate of acetylation of fatty acid cyclooxygenase (prostaglandin synthase, EC 1.14.99.1) by [acetyl-3H]-aspirin was measured in microsomes from human aortas and coronary arteries and intact and disrupted human platelets. We also measured the inhibition by aspirin of prostacyclin generation from exogenous arachidonic acid in shredded human aorta. Cyclooxygenase in human aorta and coronary artery microsomes is approximately 1/250th as sensitive to aspirin as enzyme in intact platelets, and 1/60th as sensitive to aspirin as enzyme measured in a platelet microsomal preparation. On the basis of the in vitro data presented, we predict that small oral doses of aspirin are sufficient to inhibit platelet prostaglandin production but are not sufficient to substantially affect aorta or coronary artery prostaglandin production.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 105363      PMCID: PMC336289          DOI: 10.1073/pnas.75.10.5181

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  14 in total

1.  Cultured human skin fibroblasts and arterial cells produce a labile platelet-inhibitory prostaglandin.

Authors:  N L Baenziger; M J Dillender; P W Majerus
Journal:  Biochem Biophys Res Commun       Date:  1977-09-09       Impact factor: 3.575

2.  Aspirin and thromboembolism--a possible dilemma.

Authors:  A J Marcus
Journal:  N Engl J Med       Date:  1977-12-08       Impact factor: 91.245

3.  Effects of salicylates on human platelets.

Authors:  J R O'Brien
Journal:  Lancet       Date:  1968-04-13       Impact factor: 79.321

4.  Aspirin selectively inhibits prostaglandin production in human platelets.

Authors:  J B Smith; A L Willis
Journal:  Nat New Biol       Date:  1971-06-23

5.  Lack of covalent modification of prostaglandin synthetase (cyclo-oxygenase) by indomethacin.

Authors:  N Stanford; G J Roth; T Y Shen; P W Majerus
Journal:  Prostaglandins       Date:  1977-04

6.  The chemical structure of prostaglandin X (prostacyclin).

Authors:  N Whittaker; S Bunting; J Salmon; S Moncada; J R Vane; R A Johnson; D R Morton; J H Kinner; R R Gorman; J C McGuire; F F Sun
Journal:  Prostaglandins       Date:  1976-12

7.  The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein.

Authors:  G J Roth; P W Majerus
Journal:  J Clin Invest       Date:  1975-09       Impact factor: 14.808

8.  Comparative effects of aspirin and diflunisal on prostaglandin synthetase from human platelets and sheep seminal vesicles.

Authors:  P W Majerus; N Stanford
Journal:  Br J Clin Pharmacol       Date:  1977-02       Impact factor: 4.335

9.  Inhibition of platelet prostaglandin synthetase by oral aspirin.

Authors:  J W Burch; N Stanford; P W Majerus
Journal:  J Clin Invest       Date:  1978-02       Impact factor: 14.808

10.  A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction.

Authors:  P C Elwood; A L Cochrane; M L Burr; P M Sweetnam; G Williams; E Welsby; S J Hughes; R Renton
Journal:  Br Med J       Date:  1974-03-09
View more
  25 in total

Review 1.  Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  John W Eikelboom; Jack Hirsh; Frederick A Spencer; Trevor P Baglin; Jeffrey I Weitz
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 2.  Adventures in vascular biology: a tale of two mediators.

Authors:  S Moncada
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-05-29       Impact factor: 6.237

3.  Biochemical selectivity of oral versus intravenous aspirin in rats. Inhibition by oral aspirin of cyclooxygenase activity in platelets and presystemic but not systemic vessels.

Authors:  C Cerletti; M C Gambino; S Garattini; G de Gaetano
Journal:  J Clin Invest       Date:  1986-07       Impact factor: 14.808

4.  Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function.

Authors:  F Bochner; D B Williams; P M Morris; D M Siebert; J V Lloyd
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

5.  Rapid recovery of in vivo prostacyclin formation after inhibition by aspirin. Evidence from measurements of the major urinary metabolite of prostacyclin by GC-MS.

Authors:  O Vesterqvist
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 6.  Arachidonate metabolism in vascular disorders.

Authors:  P W Majerus
Journal:  J Clin Invest       Date:  1983-11       Impact factor: 14.808

7.  Release of prostacyclin from the human pulmonary vascular bed in response to cholinergic stimulation.

Authors:  R Brandt; A Dembińska-Kieć; R Korbut; R J Gryglewski; J Nowak
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-01       Impact factor: 3.000

8.  [Low-dose acetylsalicylic acid (100 mg/day) following aortocoronary bypass operation].

Authors:  M Weber; C von Schacky; R Lorenz; W Meister; J Kotzur; B Reichart; K Theisen; P C Weber
Journal:  Klin Wochenschr       Date:  1984-05-15

9.  Inhibition of prostacyclin by treatment of endothelium with aspirin. Correlation with platelet adherence.

Authors:  R L Czervionke; J B Smith; G L Fry; J C Hoak; D L Haycraft
Journal:  J Clin Invest       Date:  1979-05       Impact factor: 14.808

10.  Aspirin inhibits interleukin 1-induced prostaglandin H synthase expression in cultured endothelial cells.

Authors:  K K Wu; R Sanduja; A L Tsai; B Ferhanoglu; D S Loose-Mitchell
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.